InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Price Performance

NYSE NSPR opened at $2.48 on Friday. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.67. The firm has a market capitalization of $61.83 million, a P/E ratio of -3.35 and a beta of 0.93. The company has a 50-day moving average price of $2.65 and a 200-day moving average price of $2.56.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the previous year, the company earned ($0.24) EPS. As a group, equities research analysts anticipate that InspireMD will post -0.82 EPS for the current year.

Institutional Investors Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC bought a new position in InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD at the end of the most recent quarter. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.